US Market for Minimally Invasive Vertebral Compression Fracture Treatments to See Slow Growth

By Contrast, the Global Market Will Gain Momentum Through 2015, According to Millennium Research Group

TORONTO--(BUSINESS WIRE)-- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the United States, the world’s largest market for minimally invasive vertebral compression fracture (MIVCF) treatments will continue to see subpar growth in these procedures. Two studies published in the New England Journal of Medicine in late 2009 found no difference in outcomes between vertebroplasty and a sham procedure, resulting in reluctance on the part of physicians to refer patients for these procedures. Vertebral augmentation volumes were also negatively affected by the publicity surrounding vertebroplasty treatments, but to a lesser extent.

As a result, recovery in volumes will be stronger for vertebral augmentation than for vertebroplasty. These procedures were not directly investigated, and companies like Medtronic Spinal & Biologics, which dominates the vertebral augmentation market, devote significant effort to differentiating their balloon kyphoplasty from vertebroplasty. In 2010, two new players entered the vertebral augmentation market. These included a large player in the vertebroplasty market, Stryker Interventional Spine, with its iVAS product, as well as CareFusion with its AVAmax Vertebral Balloon product. Growing competition in this segment will challenge Medtronic Spinal & Biologics’ currently dominant position.

“The growth of the elderly segment of the population means that MIVCF treatments overall will still show growth, despite these issues,” said MRG Analyst Andrew Lee. “The United States makes up a large portion of the global MIVCF treatment market, so the overall health of the market depends on success in the US. Outside the US, we’ll be seeing a lot of growth in other regions, where the procedures are relatively new. In particular, the Asia Pacific region will exhibit substantial growth through 2015. Driving this growth is the recent approval for reimbursement of Medtronic Spinal & Biologics’ balloon kyphoplasty system in Japan. This is the first MIVCF treatment approved for reimbursement there. With Japan’s large elderly population, we expect to see significant growth in the number of these procedures.”

Through 2015, the Asia Pacific market for MIVCF treatments will grow at an average of 36 percent annually. As more surgeons continue to be trained on using this device, over 97 percent of MIVCF treatments performed in Japan will be vertebral augmentations by 2015.

Millennium Research Group’s Global Markets for Minimally Invasive Vertebral Compression Fracture Treatments 2011 report includes procedure, average selling price, and revenue information for vertebroplasty and vertebral augmentation in the US, Europe (France, Germany, Italy, UK), and Asia Pacific (Australia, Japan, South Korea) markets.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]
or
Millennium Research Group
Alex Jablokow, 617-599-8613
[email protected]

KEYWORDS:   North America  Canada

INDUSTRY KEYWORDS:   Health  Medical Devices  Physical Therapy

MEDIA:

Logo
 Logo

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.